On this page you will find information about and links to relevant useful publications
You can view recent and useful publications on the topic of Breast Reconstruction here
You can view recent and useful publications on the topic of Management of the Axilla here
You can view recent and useful publications on the topic of Neoadjuvant Systematic Therapy here
This is a phase 3, double-blind, randomised trial which recruited HER2- early breast cancer patients with BRCA1/2 germline pathogenic or likely pathogenic variants (n=1836). Study participants received local therapy with adjuvant or neoadjuvant chemotherapy with patients subsequently randomised to 1 year or Olaparib or placebo. At median follow up of 2.5 years, the 3-year invasive DFS was 85.9% in the Olaparib v. 77.1% in the placebo group (HR for invasive disease or death; 0.58; p<0.001). The 3-year distant DFS was 87.5% in the Olaparib group and 80.4% in the placebo group (HR for distant disease or death; 0.57; p<0.001). No excess serious adverse events were identified with Olaparib administration. Therefore, adjuvant Olaparib was associated with significantly longer survival free of invasive or distant disease in this patient group.